Lilly's Taltz meets in Phase III for TNF inhibitor-experienced ankylosing spondylitis

Eli Lilly and Co. (NYSE:LLY) said Taltz ixekizumab met the primary endpoint of a greater proportion of patients achieving

Read the full 199 word article

User Sign In